DrugPatentWatch Database Preview
Biologic Drugs With Mechanism of Action: Interleukin 2 Receptor Antagonists
Email this page to a colleague
Biologic Drugs With Mechanism of Action: Interleukin 2 Receptor Antagonists
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | SIMULECT | basiliximab | VIAL; SINGLE-USE | 103764 | 001 | 1998-05-12 | ⤷ Free Forever Trial | UNIVERSITY OF WYOMING (Laramie, WY) | 2036-03-11 | RX | search | |
| Novartis | SIMULECT | basiliximab | VIAL; SINGLE-USE | 103764 | 001 | 1998-05-12 | ⤷ Free Forever Trial | AiCuris GmbH & Co. KG (Wuppertal, DE) | 2028-05-08 | RX | search | |
| Novartis | SIMULECT | basiliximab | VIAL; SINGLE-USE | 103764 | 001 | 1998-05-12 | ⤷ Free Forever Trial | CureVac AG (Tubingen, DE) | 2032-02-15 | RX | search | |
| Novartis | SIMULECT | basiliximab | VIAL; SINGLE-USE | 103764 | 001 | 1998-05-12 | ⤷ Free Forever Trial | Universitatsklinikum Freiburg (Freiburg, DE) Medizinische Universitat Wien (Vienna, AT) | 2031-12-22 | RX | search | |
| Novartis | SIMULECT | basiliximab | VIAL; SINGLE-USE | 103764 | 001 | 1998-05-12 | ⤷ Free Forever Trial | University of Maryland, Baltimore (Baltimore, MD) The United States of America as Represented by the Department of Veteran Affairs (Washington, DC) | 2027-01-12 | RX | search | |
| Novartis | SIMULECT | basiliximab | VIAL; SINGLE-USE | 103764 | 001 | 1998-05-12 | ⤷ Free Forever Trial | Memorial Sloan Kettering Cancer Center (New York, NY) | 2035-02-05 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
